Earlier this week, Allergan plc announced two pivotal trials for the Oculeve Intranasal Tear Neurostimulator had met their primary and secondary efficacy endpoints, and the company was on-track to provide a premarket submission to the US Food and Drug Administration (FDA) for the device in the second half of 2016.
According to Allergan, the Oculeve Intranasal Tear Neurostimulator is a handheld stimulator used to help increase tear production in patients with dry eye disease. The company had conducted several clinical studies showing the safety and efficacy of the device with more than 200 adult patients.
Click here to read the full article.